Hydroxyurea Pharmacokinetic Evaluation in Patients with Sickle Cell Disease.

Hydroxyurea (HU), also known as hydroxycarbamide, is an oral ribonucleotide reductase inhibitor. In 1999, the United States Food and Drug Administration (FDA) approved HU for the treatment of sickle cell disease (SCD). Since then, it has become the cornerstone in the management of SCD patients, helping to reduce vaso-occlusive crises, acute chest syndrome, the need for blood transfusions, hospitalizations and mortality.

[A case of cardiogenic syncope in a drug-addict patient].

Torsade de pointes is a polymorphic ventricular tachycardia, associated with prolonged QT interval and characterized by twisting of the mean electrical axis of the QRS complexes around an isoelectric line. The long QT syndrome can be divided into two categories, congenital and acquired. The congenital long QT syndrome may be caused by some gene mutation, whereas the acquired form is usually associated with drugs and electrolyte imbalance.

[Measurement of carotid intima-media thickness and of pressure variability in arterial hypertension in menopause].

Forty women, with hypertension developed during menopause, were divided into two groups, depending on whether from the time of its beginning there were occurrences of clinic episodes expressing a more or less acute "organ damage" or not. In all patients a 24 hrs ambulatory blood pressure monitoring and a carotid ultrasound were carried out to evaluate the carotid intima-media thickness (IMT). The IMT resulted significantly superior in those patients presenting a vascular episode and as much significantly correlated to the pressure values, especially systolic; in particular, in "non dippers" patients there is evidence of correlations between percentages of "at risk" systolic pressure peaks, prevalence of plaques in carotidal vessels and higher IMT compared to those patients with night-time blood pressure decrease.